SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Brennan MF, Alektiar KM, Maki RG. Sarcomas of the soft tissue and bone. In: DeVitaVT, HellmanS, RosenbergSA, editors. Cancer: principles and practice of oncology (6th edition). Philadelphia: Lippincott Williams & Wilkins, 2001: 18411891.
  • 2
    Spath-Schwalbe E, Genvress I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs. 2000; 11: 325329.
  • 3
    Merimsky O, Meller I, Flusser G, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a Phase II study. Cancer Chemother Pharmacol. 2000; 45: 177181.
  • 4
    Plunkettt W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action and self-potentiation. Semin Oncol. 1995; 22: 310.
  • 5
    Grunewald R, Abbruzzese JL, Tarasoff P, Plunkett W. Saturation or 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a Phase I trial of gemcitabine. Cancer Chemother Pharmacol. 1991; 27: 258262.
  • 6
    Abbruzzese JL, Grunewald R, Weeks EA, et al. A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991; 9: 491498.
  • 7
    Brand R, Capadano M, Tempero M. A Phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs. 1997; 15: 331341.
  • 8
    Touroutoglou N, Gravel M, Raber N, Plunkett W, Abbruzzese JL. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol. 1998; 9: 10031008.
  • 9
    Ulrich-Pur H, Kornek GV, Raderer M, et al. A Phase I trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer. 2000; 88: 25052511.
  • 10
    Friedman HS, Averbuch SD, Kurtzberg J. Nonclassic alkylating agents. In: ChabnerBA, LongoDL, editors. Cancer chemotherapy and biotherapy (3rd edition). Philadelphia: Lippincott Williams & Wilkins, 2001: 415446.
  • 11
    Buesa JM, Urréchaga E. Clinical pharmacokinetics of high-dose DTIC. Cancer Chemother Pharmacol. 1992; 28: 475479.
  • 12
    Buesa JM, Gracia M, Valle M, Estrada E, Hidalgo OF, Lacave AJ. Phase I trial of intermittent high-dose dacarbazine. Cancer Treat Rep. 1984; 68: 499504.
  • 13
    Gottlieb JA, Benjamin RS, Baker LH, et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep. 1976; 60: 199203.
  • 14
    Buesa JM, Mouridsen HT, van Oosterom AT, et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A Phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol. 1991; 2: 307309.
  • 15
    National Cancer Institute Cancer Therapy Evaluation Program. Common toxicity criteria. Version 2.0. Bethesda: National Cancer Institute, 1998.
  • 16
    Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer. 1981; 47: 207214.
  • 17
    Kroep JR, Giaconne G, Voorn DA, et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small cell lung cancer. J Clin Oncol. 1999; 17: 21902197.
  • 18
    Losa R, Sierra MI, Blay P, Blanco D, Buesa JM. Determination of gemcitabine triphosphate in peripheral blood mononuclear cells by reverse-phase HPLC. Chromatographia. 2004; 59: 78.
  • 19
    Martin C, Pollera CF. Gemcitabine: safety profile unaffected by starting dose. Int J Clin Pharmacol Res. 1996; 16: 918.
  • 20
    Fossella FV, Lippman SM, Shin DM, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a Phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997; 15: 310316.
  • 21
    Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized Phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003; 21: 34023408.
  • 22
    Penz M, Kornek GV, Raderer M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol. 2001; 12: 183186.
  • 23
    Ceci G, Bella M, Melissari M, Gabrielli M, Bocchi P, Cocconi G. Fatal hepatic vascular toxicity of DTIC. Is it really a rare event? Cancer. 1988; 61: 19881991.
  • 24
    Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: a Phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol. 1992; 10: 406413.
  • 25
    Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res. 1990; 50: 68236826.
  • 26
    Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001; 19: 34833489.
  • 27
    Gandhi V, Plunkett W, Du M, Ayres M, Estey EH. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a Phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol. 2002; 20: 665673.
  • 28
    Svancarova L, Blay JL, Judson IR, et al. Gemcitabine in advanced adult soft-tissue sarcomas. A Phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002; 38: 556559.
  • 29
    Okuno S, Ryan LM, Edmonson JH, Priebat DA, Blum RH. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797). A trial of the Eastern Cooperative Oncology Group. Cancer. 2003; 97: 19691973.
  • 30
    Burton GV, Rankin C, Flaherty LE, et al. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcomas [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 820.
  • 31
    Amodio A, Carpano S, Manfredi C, et al. Gemcitabine in advanced stage soft tissue sarcoma: a Phase II study. Clin Ther. 1999; 150: 1720.
  • 32
    Samuels BL, Barbour L, Schiller D. Phase I study of low dose continuous infusion gemcitabine in sarcoma patients [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 296b.
  • 33
    Gautam U, Hurley J, Silva OE, et al. Gemcitabine: an active chemotherapeutic agent for angiosarcoma [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 278b.
  • 34
    Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J Clin Oncol. 2002; 20: 28242831.
  • 35
    Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of osteosarcoma. J Clin Oncol. 2004; 22: 17061712.